Tesetaxel, a new oral taxane, in combination with capecitabine: A phase I, dose-escalation study in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 6, 2011, Pages 1565-1573

  Saif, Muhammad Wasif ^a,c   Sarantopoulos, John ^b,d   Patnaik, Amita ^b   Tolcher, Anthony W ^b   Takimoto, Chris ^b,e   Beeram, Murali ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b CTRC Institute for Drug Development   (United States)

^c Herbert Irving Cancer Center ^*  (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e CENTOCOR INC   (United States)

Author keywords

Advanced solid tumors; Capecitabine; Oral fluoropyrimidine; Oral taxane; Tesetaxel

Indexed keywords

5' DEOXY 5 FLUOROCYTIDINE; ALKYLATING AGENT; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; CAPECITABINE; CARBOPLATIN; DNA TOPOISOMERASE INHIBITOR; DOXIFLURIDINE; ERYTHROPOIETIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOMYCIN C; MONOCLONAL ANTIBODY; NITROSOUREA; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TESETAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOKALEMIA; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERONEUS NERVE PARALYSIS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TAXOIDS;

EID: 82455162574     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1639-3     Document Type: Article

References (12)

1. M Shionoya T Jimbo M Kitagawa T Soga A Tohgo 2003 DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo Cancer Sci 94 459 466 12824894 10.1111/j.1349-7006.2003.tb01465.x 1:CAS:528:DC%2BD3sXls1WrtLY%3D (Pubitemid 36790480)
2. Tohgo A, Shionoya M, Iwahana M, Uesugi Y, Jimbo T, Soga T (2002) DJ-927, a novel orally active taxane: 1. Preclinical antitumor activity and toxicity profile. Proceedings of the AACR 43:790 (Abstract 3916)
3. Chan S, Paridaens R, Awada A, Mukherjee A, Lawton P, Dumez H et al (2004) Efficacy and prediction of response to the new oral taxane DJ-927 in anthacycline pre-treated advanced breast cancer (ABC). Eur J Cancer Suppl 4 (No.12):193 (Abstract 641)
4. Evans T, Dobrila R, Berardi R, Sumpter KA, Wall LR, Oyama R et al (2006) A Phase II study of DJ-927 as second-line therapy in patients (pts) with advanced gastric cancer (GC) who have failed a 5-FU non taxane based regimen. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. 24 (No. 18S) (Abstract 4081)
5. Moore MR, Jones C, Harker G, Lee F, Ardalan B, Saif MW et al (2006) Phase II trial of DJ-927, an oral tubulin depolymerization inhibitor, in the treatment of metastatic colorectal cancer. J Clin Oncol ASCO Annual Meeting Proceedings Part I. 24 (No. 18S) (Abstract 3591)
6. T Ishikawa M Utoh N Sawada M Nishida Y Fukase F Sekiguchi, et al. 1998 Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts Biochem Pharmacol 55 1091 1097 9605432 10.1016/S0006-2952(97)00682-5 1:CAS:528:DyaK1cXitlSiurk%3D (Pubitemid 28167730)
7. JF Maher MA Villalona-Calero 2002 Taxanes and capecitabine in combination: rationale and clinical results Clin Breast Cancer 2 287 293 11899360 10.3816/CBC.2002.n.004 1:CAS:528:DC%2BD38Xns1Wjurk%3D (Pubitemid 34196271)
8. Xeloda™ prescribing information. Genentech USA, Inc
9. PM Hoff R Ansari G Batist J Cox W Kocha M Kuperminc, et al. 2001 Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study J Clin Oncol 19 2282 2292 11304782 1:CAS:528:DC%2BD3MXjsFeqsrw%3D (Pubitemid 32366981)
10. E Van Cutsem C Twelves J Cassidy D Allman E Bajetta M Boyer, et al. 2001 Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study J Clin Oncol 19 4097 4106 11689577 (Pubitemid 33049527)
11. J O'Shaughnessy D Miles S Vukelja V Moiseyenko JP Ayoub G Cervantes, et al. 2002 Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J Clin Oncol 20 2812 2823 12065558 10.1200/JCO.2002.09.002 (Pubitemid 34651510)
12. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein, et al. 2000 New guidelines to evaluate the response to treatment of solid tumors J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280: DC%2BD3c7it1Gitg%3D%3D (Pubitemid 30099779)